Related Experiment Video
Updated: Aug 21, 2025
13:20
Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro
Published on: July 17, 2018
10.4K
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting
Yoshimi Endo Greer1, Lidia Hernandez1, Emily M J Fennell2
1Women's Malignancies Branch, NCI, NIH, Bethesda, MD.
Cancer Research Communications
|November 17, 2022
Summary
Mitochondrial ClpP agonists inhibit breast cancer stem cell growth by disrupting mitochondrial function and key metabolic pathways. This targeted approach shows promise for overcoming treatment resistance and metastasis.
Area of Science:
- Mitochondrial biology
- Cancer stem cell biology
- Metabolic pathways
Background:
- Mitochondria are crucial for cancer cell energy and biosynthesis.
- Cancer stem cells (CSCs) drive tumor growth, metastasis, and therapy resistance.
- Breast CSCs rely on oxidative phosphorylation (OxPhos), unlike bulk cancer cells.
Purpose of the Study:
- To investigate the efficacy of ClpP agonists in inhibiting breast cancer cell proliferation and CSC function.
- To elucidate the underlying mechanisms of ClpP agonist action on CSCs.
- To compare ClpP agonists with other mitochondria-targeting drugs.
Main Methods:
- In vitro and in vivo studies using breast cancer models.
- Analysis of mitochondrial function, including OxPhos.
- Assessment of metabolic pathways (mevalonate, NAD(P)+/NAD(P)H, one-carbon, proline biosynthesis) and signaling pathways (YAP, Myc, HIF).
Main Results:
- ClpP agonists significantly inhibited breast cancer cell proliferation and CSC function.
- OxPhos inhibition by ClpP agonists downregulated critical CSC pathways.
- ClpP agonists depleted NAD(P)+/NAD(P)H, induced redox imbalance, and dysregulated key metabolic pathways.
- ClpP agonists demonstrated superior efficacy compared to other mitochondria-targeting drugs.
Conclusions:
- ClpP agonists effectively inhibit breast CSC functions by disrupting mitochondrial homeostasis.
- Targeting ClpP disrupts multiple essential metabolic and signaling pathways in breast CSCs.
- ClpP agonists represent a promising therapeutic strategy against breast cancer stem cells.
More Related Videos
07:03Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
Published on: October 2, 2020
4.6K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.8K
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K